Ibogaine for Opioid Use Disorder: An Unrecognized Risk.
Journal of addiction medicine – January 15, 2026
Source: PubMed
Summary
A critical safety concern arises as interest in ibogaine, a psychedelic, expands for opioid use disorder. Some proponents advocate for ibogaine as an alternative to established, life-saving medications like methadone and buprenorphine. Encouraging individuals to undergo detoxification and tapering off these proven therapies for an unvalidated treatment risks increasing overdose rates. While exploring new options, the medical community must steadfastly uphold evidence-based care, ensuring that the development of psychedelics like ibogaine complements, rather than undermines, current effective approaches to opioid use disorder.
Abstract
The psychedelic substance, ibogaine, has garnered growing interest among policymakers, researchers, and the public in its potential use for opioid use disorder (OUD). Many states are allocating significant funds to investigate it further. However, some proponents of ibogaine are framing it in opposition to (versus complementary to) standard, mortality-reducing medications for OUD (MOUD). Although the path to OUD remission and recovery varies greatly among individuals, the stakes are high: "detoxification" from methadone or buprenorphine in favor of an as-yet unproven therapy like ibogaine could result in an increased risk of opioid overdose for some. The addiction medicine community should be aware of this potential risk and defend evidence-based care, even as treatments like ibogaine are developed for OUD.